Spain · Delayed Price · Currency is EUR Oryzon Genomics Statistics
Total Valuation
Oryzon Genomics has a market cap or net worth of EUR 239.17 million. The enterprise value is 235.28 million.
| Market Cap | 239.17M |
| Enterprise Value | 235.28M |
Important Dates
The next estimated earnings date is Wednesday, October 28, 2026.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oryzon Genomics has 81.96 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 81.96M |
| Shares Outstanding | 81.96M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 13.17% |
| Owned by Institutions (%) | 2.55% |
| Float | 64.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.52 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.60 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.16 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2.08% and return on invested capital (ROIC) is -2.83%.
| Return on Equity (ROE) | -2.08% |
| Return on Assets (ROA) | -2.66% |
| Return on Invested Capital (ROIC) | -2.83% |
| Return on Capital Employed (ROCE) | -17.52% |
| Weighted Average Cost of Capital (WACC) | 6.38% |
| Revenue Per Employee | 334,939 |
| Profits Per Employee | -52,791 |
| Employee Count | 46 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 37.79 |
Taxes
| Income Tax | -3.55M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.08% in the last 52 weeks. The beta is 0.44, so Oryzon Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +13.08% |
| 50-Day Moving Average | 3.00 |
| 200-Day Moving Average | 3.03 |
| Relative Strength Index (RSI) | 49.59 |
| Average Volume (20 Days) | 266,509 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oryzon Genomics had revenue of EUR 15.41 million and -2.43 million in losses. Loss per share was -0.03.
| Revenue | 15.41M |
| Gross Profit | 15.06M |
| Operating Income | -5.94M |
| Pretax Income | -5.97M |
| Net Income | -2.43M |
| EBITDA | -19.51M |
| EBIT | -22.76M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 14.69 million in cash and 10.80 million in debt, with a net cash position of 3.89 million or 0.05 per share.
| Cash & Cash Equivalents | 14.69M |
| Total Debt | 10.80M |
| Net Cash | 3.89M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 119.70M |
| Book Value Per Share | 1.54 |
| Working Capital | 6.37M |
Cash Flow
In the last 12 months, operating cash flow was -4.91 million and capital expenditures -87,669, giving a free cash flow of -5.00 million.
| Operating Cash Flow | -4.91M |
| Capital Expenditures | -87,669 |
| Depreciation & Amortization | 99,425 |
| Net Borrowing | -1.33M |
| Free Cash Flow | -5.00M |
| FCF Per Share | -0.06 |
Margins
Gross margin is 97.75%, with operating and profit margins of -38.56% and -15.76%.
| Gross Margin | 97.75% |
| Operating Margin | -38.56% |
| Pretax Margin | -38.77% |
| Profit Margin | -15.76% |
| EBITDA Margin | -37.91% |
| EBIT Margin | -38.56% |
| FCF Margin | n/a |
Dividends & Yields
Oryzon Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | -1.02% |
| FCF Yield | -2.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Oryzon Genomics is 7.13, which is 142.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 7.13 |
| Price Target Difference | 142.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 111.55% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oryzon Genomics has an Altman Z-Score of 6.54 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.54 |
| Piotroski F-Score | 3 |